Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.68 | N/A | +17.65% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.68 | N/A | +17.65% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management highlighted their focus on maintaining operational efficiency. However, they did not provide detailed insights into future performance.
Management did not provide specific revenue figures or future guidance.
The company expressed confidence in its operational strategies.
Repligen Corp reported better-than-expected earnings per share, but the lack of revenue data and guidance may have raised concerns among investors. The stock fell 4.51% in response, indicating that the market may have been looking for more comprehensive information on future performance. Investors will likely be watching closely for any updates in the coming quarters.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PHOTRONICS INC
Feb 20, 2023